H3 influenza A virus
AssigneeWisconsin Alumni Research Foundation (WARF)
InventorsChristopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
Life of this patent
Estimating the term…
Abstract
The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
Claims20
A vaccine comprising an isolated H3 influenza virus comprising HA-1 having a sequence having at least 96% amino acid sequence identity to the HA-1 portion of SEQ ID NO:
- 1 and having an alanine at position 78 and a serine at position 159, in an amount effective to induce a prophylactic or therapeutic response against influenza infection, wherein the virus is inactivated, the vaccine is in freeze-dried form or the vaccine further comprises an adjuvant.
A method to immunize a mammal against influenza, comprising administering to the mammal an effective amount of a composition comprising an isolated H3 influenza virus comprising HA-1 having a sequence having at least 96% amino acid sequence identity to the HA-1 portion of SEQ ID NO:1 and having an alanine at position 78 and a serine at position 159.
A method of preparing a vaccine, comprising
- combining an isolated H3 influenza virus comprising HA-1 having a sequence having at least 96% amino acid sequence identity to the HA-1 portion of SEQ ID NO:
- 1 and having an alanine at position 78 and a serine at position 159, with an adjuvant or a pharmaceutically acceptable carrier, or treating the isolated H3 influenza virus with an agent that inactivates the isolated H3 virus or under conditions that freeze-dry the isolated H3 virus, thereby providing a composition;
- and providing an individual dose of the composition comprising an amount of the H3 influenza virus effective to immunize a canine or a horse.
Dependencies are inferred from the claim text.